Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4IQ
|
|||
| Former ID |
DIB012979
|
|||
| Drug Name |
RhGDF-5
|
|||
| Synonyms |
MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil
Click to Show/Hide
|
|||
| Indication | Periodontal disease [ICD-11: DA0C] | Phase 2 | [1] | |
| Company |
Biopharm GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 5 (GDF-5) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| TGF-beta signaling pathway | ||||
| Hippo signaling pathway | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | TGF-beta signaling pathway | |||
| Reactome | Molecules associated with elastic fibres | |||
| WikiPathways | Differentiation Pathway | |||
| Elastic fibre formation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01124006) A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration. U.S. National Institutes of Health. | |||
| REF 2 | Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.